Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5372321 | 0.99 | DRD4 (0.45) | DRD4TACR1 | |
| Hydrochloric Acid SCHEMBL5360642 | 0.99 | DRD4 (0.45) | DRD4TACR1 | |
| Hydrochloric Acid SCHEMBL5379215 | 0.96 | DRD4 (0.43) | DRD4TACR1 | |
| Hydrochloric Acid SCHEMBL5361186 | 0.95 | DRD4 (0.45) | DRD4TACR1 | |
| Hydrochloric Acid SCHEMBL6003141 | 0.95 | DRD4 (0.43) | DRD4TACR1 | |
| Hydrochloric Acid SCHEMBL5367256 | 0.95 | DRD4 (0.43) | DRD4TACR1 | |
| Hydrochloric Acid SCHEMBL5370119 | 0.95 | DRD4 (0.45) | DRD4TACR1 | |
| Hydrochloric Acid SCHEMBL5366569 | 0.93 | TACR1 (0.44) | DRD4TACR1 | |
| Hydrochloric Acid SCHEMBL5367253 | 0.93 | DRD4 (0.41) | DRD4TACR1 | |
| Hydrochloric Acid SCHEMBL5368282 | 0.93 | TACR1 (0.44) | DRD4TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123532-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2007-05-31 | — | — | US | claimed |
| US-20060014948-A1 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-01-19 | — | — | US | claimed |
| EP-1140924-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | claimed |
| WO-2000035915-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-06-22 | — | — | WO | claimed |
| EP-1140924-B1 | PIPERAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014948-A1 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals | PKD2, TAC3, PKD1 | DRD4 1628/4885TACR1 29/4885 |
| US-20070123532-A1 | PIPERAZINE DERIVATIVES | PKD2, SSTR5, IL5 | DRD4 752/4885TACR1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.